Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062

Mary E. R. O'Brien*, Krzystof Konopa, Paul Lorigan, Lionel Bosquee, Ernest Marshall, Frederique Bustin, Sabine Margerit, Christian Fink, Jos A. Stigt, Anne Marie C. Dingemans, Baktiar Hasan, Jan Van Meerbeeck, Paul Baas

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Web of Science)
Original languageEnglish
Pages (from-to)2322-2330
JournalEuropean Journal of Cancer
Issue number15
Publication statusPublished - Oct 2011


  • Small cell lung cancer
  • Amrubicin
  • Survival
  • Toxicity

Cite this